Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2759 | TNF-a | 100 | ng/mL | 1 | M-CSF | 997.0 | 43 | ||||
RA1931 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | M-CSF | 601.0 | 25 | |
RA1931 | TNF-a | 100 | ng/mL | 1 | M-CSF | 692.0 | 34 | ||||
N2586 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 1 | M-CSF | 855.0 | 44 | |
N2586 | TNF-a | 100 | ng/mL | 1 | M-CSF | 668.0 | 47 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 387.0 | 44 | |
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 504.0 | 36 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 825.5 | 46 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 612.5 | 42 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 464.0 | 48 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 502.0 | 44 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 616.0 | 37 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 623.0 | 47 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 595.0 | 47 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 597.0 | 54 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 737.5 | 32 | |
N2759 | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 716.0 | 33 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 617.0 | 39 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 609.0 | 41 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 706.0 | 35 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | M-CSF | 528.0 | 37 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | M-CSF | 218.0 | 44 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | M-CSF | 172.0 | 33 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | M-CSF | 359.0 | 41 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | M-CSF | 457.5 | 52 |